Global Information
회사소개 | 문의 | 위시리스트

연조직 종양(STS) 역학 예측(-2030년)

Soft Tissue Sarcoma (STS) - Epidemiology Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 02월 상품 코드 534995
페이지 정보 영문 122 Pages
가격
US $ 3,750 ₩ 4,581,000 PDF by E-mail (Single User License)
US $ 7,500 ₩ 9,162,000 PDF by E-mail (Site License)
US $ 11,250 ₩ 13,744,000 PDF by E-mail (Global License)


연조직 종양(STS) 역학 예측(-2030년) Soft Tissue Sarcoma (STS) - Epidemiology Forecast - 2030
발행일 : 2020년 02월 페이지 정보 : 영문 122 Pages

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 연조직 종양(STS) 총환자수는 2017년 40,155명을 기록한 것으로 추정됩니다.

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 연조직 종양(STS: Soft Tissue Sarcoma) 시장을 조사했으며, 시장 및 질환 개요, 전체 및 국가별 역학적 예측, 부문별 환자수 추이와 예측을 상세하게 정리했습니다.

목차

제1장 프리미엄 인사이트

제2장 주요 요약

제3장 연조직 종양(STS) : 개요

  • 환자 분포 상황(실수치)
  • 환자 분포 상황(예측)

제4장 질환의 배경과 개요 : 연조직 종양(STS)

  • 서론
  • 연조직 종양(STS)의 종류
  • 연조직 종양(STS)의 분자 구조
  • 연조직 종양(STS)의 병기
  • 연조직 종양(STS)의 진단
    • 병력/신체검사
    • 영상검사
    • 생검
    • 병리진단
    • 진단 가이드라인

제5장 역학과 환자 인구

  • 주요 조사결과
  • 주요 7개국의 연조직 종양(STS)

제6장 증례 보고

제7장 연조직 종양(STS) 역학 : 국가별

  • 미국
    • 전제조건과 이론적 근거
    • 연조직 종양(STS) 총환자수
    • 연조직 종양(STS) 환자수 : 종류별
    • 위장관 기질종양(GIST) 총환자수
    • 위장관 기질종양(GIST)을 포함한 연조직 종양(STS) 환자수
    • 연조직 종양(STS) 환자수 : 사지별
  • EU 5개국
    • 독일
      • 전제조건과 이론적 근거
      • 연조직 종양(STS) 총환자수
      • 연조직 종양(STS) 환자수 : 종류별
      • 위장관 기질종양(GIST) 총환자수
      • 위장관 기질종양(GIST)을 포함한 연조직 종양(STS) 환자수
      • 연조직 종양(STS) 환자수 : 사지별
    • 프랑스
      • 전제조건과 이론적 근거
      • 연조직 종양(STS) 총환자수
      • 연조직 종양(STS) 환자수 : 종류별
      • 위장관 기질종양(GIST) 총환자수
      • 위장관 기질종양(GIST)을 포함한 연조직 종양(STS) 환자수
      • 연조직 종양(STS) 환자수 : 사지별
    • 이탈리아
      • 전제조건과 이론적 근거
      • 연조직 종양(STS) 총환자수
      • 연조직 종양(STS) 환자수 : 종류별
      • 위장관 기질종양(GIST) 총환자수
      • 위장관 기질종양(GIST)을 포함한 연조직 종양(STS) 환자수
      • 연조직 종양(STS) 환자수 : 사지별
    • 스페인
      • 전제조건과 이론적 근거
      • 연조직 종양(STS) 총환자수
      • 연조직 종양(STS) 환자수 : 종류별
      • 위장관 기질종양(GIST) 총환자수
      • 위장관 기질종양(GIST)을 포함한 연조직 종양(STS) 환자수
      • 연조직 종양(STS) 환자수 : 사지별
    • 영국
      • 전제조건과 이론적 근거
      • 연조직 종양(STS) 총환자수
      • 연조직 종양(STS) 환자수 : 종류별
      • 위장관 기질종양(GIST) 총환자수
      • 위장관 기질종양(GIST)을 포함한 연조직 종양(STS) 환자수
      • 연조직 종양(STS) 환자수 : 사지별
  • 일본
    • 전제조건과 이론적 근거
    • 연조직 종양(STS) 총환자수
    • 연조직 종양(STS) 환자수 : 종류별
    • 위장관 기질종양(GIST) 총환자수
    • 위장관 기질종양(GIST)을 포함한 연조직 종양(STS) 환자수
    • 연조직 종양(STS) 환자수 : 사지별

제8장 부록

  • 조사 방법

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

LSH 20.02.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1 Summary of STS Epidemiology, and Key Events (2017-2030)
  • Table 2 The IGF System in Sarcoma Pathogenesis
  • Table 3 Trunk and Extremities Sarcoma Stages
  • Table 4 Incident Patient Population of STS in the 7MM (2017-2030)
  • Table 5 Total Incident Population of STS in the United States (2017-2030)
  • Table 6 Type-Specific Incidence of STS in the US (2017-2030)
  • Table 7 Stage-Specific Incidence of STS (Excluding GIST) in the United States (2017-2030)
  • Table 8 Total Incident Population of GIST in the United States (2017-2030)
  • Table 9 Stage-Specific Incidence of GIST in the United States (2017-2030)
  • Table 10 Total Incident Population of STS including GIST in the United States (2017-2030)
  • Table 11 Gender-Specific Incidence of STS in the United States (2017-2030)
  • Table 12 Age-Specific Incidence of STS in the United States (2017-2030)
  • Table 13 Incidence of STS* by Extremities (%) in the United States (2017-2030)
  • Table 14 Total Incident Population of STS in Germany (2017-2030)
  • Table 15 Gender-Specific Incidence of STS in Germany (2017-2030)
  • Table 16 Type-Specific Incidence of STS in Germany (2017-2030)
  • Table 17 Age-Specific Incidence of STS in Germany (2017-2030)
  • Table 18 Stage-Specific Incidence of STS in Germany (2017-2030)
  • Table 19 Incidence of STS by Extremities (%) in Germany (2017-2030)
  • Table 20 Total Incident Population of STS in France (2017-2030)
  • Table 21 Gender-Specific Incidence of STS in France (2017-2030)
  • Table 22 Type-Specific Incidence of STS in France (2017-2030)
  • Table 23 Age-Specific Incidence of STS in France (2017-2030)
  • Table 24 Stage-Specific Incidence of STS in France (2017-2030)
  • Table 25 Incidence of STS by Extremities (%) in France (2017-2030)
  • Table 26 Total Incident Population of STS in Italy (2017-2030)
  • Table 27 Gender-Specific Incidence of STS in Italy (2017-2030)
  • Table 28 Type-Specific Incidence of STS in Italy (2017-2030)
  • Table 29 Age-Specific Incidence of STS in Italy (2017-2030)
  • Table 30 Stage-Specific Incidence of STS in Italy (2017-2030)
  • Table 31 Incident of STS by Extremities (%) in Italy (2017-2030)
  • Table 32 Total Incident Population of STS in Spain (2017-2030)
  • Table 33 Gender-Specific Incidence of STS in Spain (2017-2030)
  • Table 34 Type-Specific Incidence of STS in Spain (2017-2030)
  • Table 35 Age-Specific Incidence of STS in Spain (2017-2030)
  • Table 36 Stage-Specific Incidence of STS in Spain (2017-2030)
  • Table 37 Incident of STS by Extremities (%) in Spain (2017-2030)
  • Table 38 Total Incident Population of STS in the United Kingdom (2017-2030)
  • Table 39 Gender-Specific Incidence of STS in the United Kingdom (2017-2030)
  • Table 40 Type-Specific Incidence of STS in the UK (2017-2030)
  • Table 41 Age-Specific Incidence of STS in the United Kingdom (2017-2030)
  • Table 42 Stage-Specific Incidence of STS in the United Kingdom (2017-2030)
  • Table 43 Incident of STS by Extremities (%) in the United Kingdom (2017-2030)
  • Table 44 Total Incident Population of STS in Japan (2017-2030)
  • Table 45 Gender-Specific Incidence of STS in Japan (2017-2030)
  • Table 46 Type-Specific Incidence of STS in Japan (2017-2030)
  • Table 47 Age-Specific Incidence of STS in Japan (2017-2030)
  • Table 48 Stage-Specific Incidence of STS in Japan (2017-2030)
  • Table 49 Incident of STS by Extremities (%) in Japan (2017-2030)

List of Figures

  • Figure 1 Common Types of Soft-Tissue Sarcomas (STS)
  • Figure 2 Angiosarcoma
  • Figure 3 Dermatofibrosarcoma protuberans (DFSP)
  • Figure 4 Several Growth Factor Signals Activate Cell Membrane Receptor Tyrosine Kinases Leading to Activation of Downstream Interacting Signal Transduction Pathways (PI3K/AKT, RAF/MAPK, and mTOR)
  • Figure 5 Grade Numbers of Soft-Tissue Sarcoma (STS)
  • Figure 6 Diagnosis of Soft-Tissue Sarcoma
  • Figure 7 Imaging Tests for Soft-Tissue Sarcoma (STS)
  • Figure 8 Incidence of STS in the 7MM (2017-2030)
  • Figure 9 Total Incident Cases of STS in the United States (2017-2030)
  • Figure 10 Type-Specific Incidence of STS in the United States (2017-2030)
  • Figure 11 Stage-Specific Incidence of STS (Excluding GIST) in the United States (2017-2030)
  • Figure 12 Total Incident Cases of GIST in the United States (2017-2030)
  • Figure 13 Stage-Specific Incidence of GIST in the United States (2017-2030)
  • Figure 14 Total Incident Cases of STS including GIST in the United States (2017-2030)
  • Figure 15 Gender-Specific Incidence of STS in the United States (2017-2030)
  • Figure 16 Age-Specific Incidence of STS in the United States (2017-2030)
  • Figure 17 Incidence of STS* by Extremities (%) in the United States (2017-2030)
  • Figure 18 Total Incident Cases of STS in Germany (2017-2030)
  • Figure 19 Gender-Specific Incidence of STS in Germany (2017-2030)
  • Figure 20 Type-Specific Incident of STS in Germany (2017-2030)
  • Figure 21 Age-Specific Incidence of STS in Germany (2017-2030)
  • Figure 22 Stage-Specific Incidence of STS in Germany (2017-2030)
  • Figure 23 Incidence of STS by Extremities (%) in Germany (2017-2030)
  • Figure 24 Total Incident Cases of STS in France (2017-2030)
  • Figure 25 Gender-Specific Incidence of STS in France (2017-2030)
  • Figure 26 Type-Specific Incident of STS in France (2017-2030)
  • Figure 27 Age-Specific Incidence of STS in France (2017-2030)
  • Figure 28 Stage-Specific of STS in France (2017-2030)
  • Figure 29 Incidence of STS by Extremities (%) in France (2017-2030)
  • Figure 30 Total Incident Cases of STS in Italy (2017-2030)
  • Figure 31 Gender-Specific Incidence of STS in Italy (2017-2030)
  • Figure 32 Type-Specific Incident of STS in Italy (2017-2030)
  • Figure 33 Age-Specific Incidence of STS in Italy (2017-2030)
  • Figure 34 Stage-Specific Incidence of STS in Italy (2017-2030)
  • Figure 35 Incident of STS by Extremities (%) in Italy (2017-2030)
  • Figure 36 Total Incident Cases of STS in Spain (2017-2030)
  • Figure 37 Gender-Specific Incidence of STS in Spain (2017-2030)
  • Figure 38 Type-Specific Incident of STS in Spain (2017-2030)
  • Figure 39 Age-Specific Incidence of STS in Spain (2017-2030)
  • Figure 40 Stage-Specific Incidence of STS in Spain (2017-2030)
  • Figure 41 Incident of STS by Extremities (%) in Spain (2017-2030)
  • Figure 42 Total Incident Cases of STS in the United Kingdom (2017-2030)
  • Figure 43 Gender-Specific Incidence of STS in the United Kingdom (2017-2030)
  • Figure 44 Type-Specific Incident of STS in the United Kingdom (2017-2030)
  • Figure 45 Age-Specific Incidence of STS in the United Kingdom (2017-2030)
  • Figure 46 Stage-Specific Incidence of STS in the United Kingdom (2017-2030)
  • Figure 47 Incident of STS by Extremities (%) in the United Kingdom (2017-2030)
  • Figure 48 Total Incident Cases of STS in Japan (2017-2030)
  • Figure 49 Gender-Specific Incidence of STS in Japan (2017-2030)
  • Figure 50 Type-Specific Incident of STS in Japan (2017-2030)
  • Figure 51 Age-Specific Incidence of STS in Japan (2017-2030)
  • Figure 52 Stage-Specific Incidence of STS in Japan (2017-2030)
  • Figure 53 Incident of STS by Extremities (%) in Japan (2017-2030)

DelveInsight's 'Soft Tissue Sarcoma (STS) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of STS in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.

According to DelveInsight's, STS has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030.

Soft Tissue Sarcoma (STS) - Disease Understanding

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease's clinical course.

Soft Tissue Sarcoma (STS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2030.

According to DelveInsight's, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounts for the highest number of cases of STS. In 2017, there were 12,390 incident cases of STS-which did not include GIST cases-in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.

In European countries, GIST cases are not included in the STS population. Germany had the highest incident population of STS with 4,781 cases, followed by Italy which had an incident population of 4,082 in 2017. On the other hand, Spain had the lowest incident population of 2,445 in 2017.

Soft Tissue Sarcoma (STS) Report Insights

  • The report covers a descriptive overview of the Soft Tissue Sarcoma (STS), explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology of Soft Tissue Sarcoma (STS) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Soft Tissue Sarcoma (STS): Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation by Total incident cases of STS
  • Total Incident Cases of GIST in the US
  • Stage-specific Incident cases of STS
  • Incidence of STS by Extremities (%)

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by Severity

Table of Contents

1. Key Insights

2. Executive Summary of Soft-Tissue Sarcoma (STS)

3. Soft-Tissue Sarcomas (STS) Epidemiology Overview at a Glance

  • 3.1. Total Incident Cases of Soft-Tissue Sarcomas (STS) in 2017
  • 3.2. Total Incident Cases of Soft-Tissue Sarcomas (STS) in 2030

4. Soft-Tissue Sarcomas (STS): Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Types of Soft-Tissue Sarcomas (STS)
  • 4.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)
  • 4.4. Stages of Soft-Tissue Sarcomas (STS)
  • 4.5. Diagnosis of Soft-Tissue Sarcomas (STS)
    • 4.5.1. Medical History and Physical Exam
    • 4.5.2. Imaging Tests
    • 4.5.3. Biopsy
    • 4.5.4. Pathological diagnosis of soft tissue sarcomas
    • 4.5.5. Proposed Diagnostic Guidelines

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Epidem Methodology
  • 5.3. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)

6. Case Reports

  • 6.1. Neoadjuvant chemotherapy for radiation-associated soft-tissue sarcoma (RAS): A case report
  • 6.2. Soft-Tissue Sarcoma Masquerading as a Hematoma
  • 6.3. Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report

7. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)

  • 7.1. United States Epidemiology
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States
    • 7.1.3. Type-Specific Incidence of STS in the United States
    • 7.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
    • 7.1.5. Total Incident Cases of STS including GIST in the United States
    • 7.1.6. Incidence of STS by Extremities (%) in the United States
  • 7.2. EU5 Epidemiology
    • 7.2.1. Germany
      • 7.2.1.1. Assumptions and Rationale
      • 7.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany
      • 7.2.1.3. Gender-Specific Incidence of STS in Germany
      • 7.2.1.4. Type-Specific Incidence of STS in Germany
      • 7.2.1.5. Age-Specific Incidence of STS in Germany
      • 7.2.1.6. Stage-Specific Incidence of STS in Germany
      • 7.2.1.7. Incidence of STS by Extremities (%) in Germany
    • 7.2.2. France
      • 7.2.2.1. Assumptions and Rationale
      • 7.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France
      • 7.2.2.3. Gender-Specific Incidence of STS in France
      • 7.2.2.4. Type-Specific Incidence of STS in France
      • 7.2.2.5. Age-Specific Incidence of STS in France
      • 7.2.2.6. Stage-Specific Diagnosed Incidence of STS in France
      • 7.2.2.7. Incidence of STS by Extremities (%) in France
    • 7.2.3. Italy
      • 7.2.3.1. Assumptions and Rationale
      • 7.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy
      • 7.2.3.3. Gender-Specific Incidence of STS in Italy
      • 7.2.3.4. Type-Specific Incidence of STS in Italy
      • 7.2.3.5. Age-Specific Incidence of STS in Italy
      • 7.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy
      • 7.2.3.7. Incident of STS by Extremities (%) in Italy
    • 7.2.4. Spain
      • 7.2.4.1. Assumptions and Rationale
      • 7.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain
      • 7.2.4.3. Gender-Specific Incidence of STS in Spain
      • 7.2.4.4. Type-Specific Incidence of STS in Spain
      • 7.2.4.5. Age-Specific Incidence of STS in Spain
      • 7.2.4.6. Stage-Specific Incidence of STS in Spain
      • 7.2.4.7. Incident of STS by Extremities (%) in Spain
    • 7.2.5. United Kingdom
      • 7.2.5.1. Assumptions and Rationale
      • 7.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom
      • 7.2.5.3. Gender-Specific Incidence of STS in the United Kingdom
      • 7.2.5.4. Type-Specific Incidence of STS in the United Kingdom
      • 7.2.5.5. Age-Specific Incidence of STS in the United Kingdom
      • 7.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom
      • 7.2.5.7. Incident of STS by Extremities (%) in the United Kingdom
  • 7.3. Japan Epidemiology
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan
    • 7.3.3. Gender-Specific Incidence of STS in Japan
    • 7.3.4. Type-Specific Incidence of STS in Japan
    • 7.3.5. Age-Specific Incidence of STS in Japan
    • 7.3.6. Stage-Specific Incidence of STS in Japan
    • 7.3.7. Incident of STS by Extremities (%) in Japan

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Back to Top
전화 문의
F A Q